Second generation inhibitors, such as the azaindole-derivative compounds Vemurafenib and Dabrafenib, and the pyrimidine- derivative compound Encorafenib, have demonstrated significant clinical efficacy and improved survival in patients with BRAFV600E melanoma [202].While Vemurafenib, Dabrafenib, and Encorafenib are selective BRAF inhibitors used in BRAF V600E mutated melanomas [203], limited data exist on their effectiveness against BRAF fusion kinase due to the low occurrence of these alterations in cell lines [201]. Here, BRAF is linked to melanoma.